- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Phase 1 Trial
Recent news which mentions Phase 1 Trial
Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
March 16, 2022
From Benzinga
Ideaya Biosciences' IDE397 Shows Preliminary Tolerability In Early-Stage Solid Tumor Trial
March 15, 2022
From Benzinga
From Benzinga
Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer
February 17, 2022
Tickers
ALKS
From Benzinga
Enanta Pharma Commences Dosing In Phase 1 COVID-19 Trial
February 16, 2022
Tickers
ENTA
From Benzinga
Amgen Posts Latest Batch of Lumakras Data In Pancreatic Cancer
February 15, 2022
Tickers
AMGN
From Benzinga
Moleculin Biotech Annamycin Doublet Therapy Shows 68% Overall Survival In Animal Study
February 14, 2022
Tickers
MBRX
From Benzinga
Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform
February 14, 2022
Tickers
AVCO
From Benzinga
UNITY Biotech Stock Jumps On Additional Data From UBX1325 Trial In Vascular Eye Disease
February 14, 2022
Tickers
UBX
From Benzinga
Pardes Biosciences Shares Early Data From COVID-19 Study
February 14, 2022
Tickers
PRDS
From Benzinga
FDA Clears Cidara Therapeutics' Phase 1 Trial For Immunotherapeutic Antiviral For Influenza
February 14, 2022
Tickers
CDTX
From Benzinga
RegenXBio Posts Updated Data From Hunter Syndrome Gene Therapy Trial
February 09, 2022
Tickers
RGNX
From Benzinga
4D Molecular Shares Updated Data From Fabry Disease Trial
February 09, 2022
Tickers
FDMT
From Benzinga
After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data
February 09, 2022
Tickers
AVRO
From Benzinga
CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19
February 04, 2022
Tickers
ACLX
From Benzinga
Pardes Biosciences Clears IND Application For Oral Antiviral Candidate For COVID-19
February 03, 2022
Tickers
PRDS
From Benzinga
4D Pharma's Asthma Candidate Shows Positive Trends In Multiple Secondary Endpoints Of Efficacy
January 27, 2022
Tickers
LBPS
From Benzinga
Sellas Life Sciences Shares Jump As China Approves Galinpepimut IND For Blood Cancer
January 27, 2022
Tickers
SLS
From Benzinga
Vaccinex Posts Two Complete Responses In Pepinemab Combo Trial In Head & Neck Cancer
January 26, 2022
From Benzinga
Two Organizations To Support Wave Life Sciences' FTD, ALS Program
January 26, 2022
Tickers
WVE
From Benzinga
89bio's NASH Candidate Shows Improvement In Disease Severity, Cardiovascular Health
January 25, 2022
Tickers
ETNB
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.